In This Section      
 

Search Results

A total of 47 matching records were found.

ETCTN10020
10020 A Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10061
A Phase 1 Study of MK-3475 (pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors (NCI#10061)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10070
Phase 1/2 study of navitoclax plus vistusertib in patients with relapsed small cell lung cancer (SCLC) and other solid tumors (ETCTN10070)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10129
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (ETCTN10129)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10131
A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel (ETCTN10131)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10170
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (ETCTN10170)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J12121
A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J13104
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)

Sites: Suburban Hospital, Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J14166
Prospective evaluation of high-dose (8 g/m2) systemic methotrexate in patients with breast cancer and leptomeningeal metastasis

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1480
My Pathway: MY PATHWAY: AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB, AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS(Protocol Number: ML28897/PRO 02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15221
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (NCI# 9844)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1564
“The IDEA Study (Individualized Decisions for Endocrine therapy Alone): A prospective, single-arm cohort study of patients receiving endocrine therapy alone (without radiotherapy) after breast conserving surgery for early-stage, post-menopausal breast cancer patients whose tumors have favorable biologic features”

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Suburban Hospital, Sibley Memorial Hospital

J1581
STM-03: Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16108
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16121
Improving Outcomes for Younger Breast Cancer Survivors: A Phase III Randomized Trial Targeting Behavioral Symptoms in Younger Breast Cancer Survivors. The Pathways to Wellness (PTW) Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16146
IMAGE II: Individualized Molecular Analyses Guide Efforts in Breast Cancer – Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1677
J1677- A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1681
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17107
J17107 - A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Hormone Receptor-Positive Her2-Negative Breast Cancer (Morpheus-HR+ Breast Cancer)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17117
A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (CO40016)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17118
Prospective evaluation of determinants of resistance to first-line therapy with an aromatase inhibitor (AI) and a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor in hormone receptor (HR) positive metastatic breast cancer (MBC)

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J17120
Cancer, Obesity/Overweight and Insomnia (COIN) Study

Sites: Johns Hopkins Bayview Medical Center

J17121
A Phase 1, Open-Label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 Monotherapy and SNDX-6352 in Combination with Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17122
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms (CP-MGD013-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17127
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers (Protocol IT-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17138
Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function During Breast Cancer Chemotherapy: A Feasibility Study

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J17183
Title: An Open-Label, Single-Arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients (3000-01-005)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17191
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, Ilaris® (canakinumab) or Mekinist® (trametinib) (CPDR001X2103)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17194
A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1778
An Open-label, Phase I, Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors (sponsor protocol MS100015-0019)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1791
A Phase II, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma (CNIR178X2201)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18129
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1836
IMMUNe MOdulation in Early Stage Estrogen Receptor Positive Breast Cancer treated with NeoADjuvant Avelumab, Palbociclib, and Tamoxifen: the ImmunoADAPT study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1878
The Johns Hopkins Breast Cancer Program Initiative to Reduce the Discontinuation Rate of Adjuvant Endocrine Therapy through Symptom Monitoring and Management: A Feasibility Study

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA011202
A011202 A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNA011401
A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNA011502
A011502 A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer (The ABC Trial)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNA221405
A221405 A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNB51
B51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNB55
B55 A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (D081CC00006)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNEA1131
EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy versus Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNNBR003
BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNS1207
S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu-Negative Breast Cancer

Sites: Sibley Memorial Hospital, Suburban Hospital

NCTNS1418
S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than / equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

SIB16134
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer

Sites: Sibley Memorial Hospital

TBCRC034
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy (TBCRC 034)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

TBCRC039
Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer (TBCRC039)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore